(ALKS) Alkermes - Ratings and Ratios

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company specializing in the research, development, and commercialization of innovative pharmaceutical products to address significant unmet medical needs. The company operates in the United States, Ireland, and internationally, focusing on therapeutic areas such as central nervous system (CNS) disorders. Its commercial portfolio includes treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The companys pipeline encompasses clinical and preclinical product candidates targeting neurological and psychiatric conditions.

Alkermes marketed products include ARISTADA, an intramuscular injectable suspension for schizophrenia; ARISTADA INITIO, designed for initiation of schizophrenia treatment in adults; VIVITROL, used for alcohol dependence treatment and opioid relapse prevention; and LYBALVI, an oral atypical antipsychotic for schizophrenia and bipolar I disorder. The company also licenses its proprietary technology platforms to third parties, enabling the development, commercialization, and manufacturing of pharmaceutical products. Key collaboration agreements are in place with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Founded in 1987, Alkermes plc is headquartered in Dublin, Ireland. Web URL: https://www.alkermes.com

Ticker Symbol: ALKS Exchange: NASDAQ Type: common stock Country Origin: Ireland GICS Sub Industry: Biotechnology

3-Month Forecast: Based on and , Alkermes plc is expected to experience moderate volatility. The stocks SMA 20 (28.98) and SMA 50 (32.39) suggest a potential downtrend in the near term, while the ATR (1.17) indicates manageable volatility. With a forward P/E of 16.39 and P/S of 2.96, the stock may face pressure from revenue growth expectations. However, the companys RoE of 25.06% reflects strong operational efficiency, which could support long-term value. Average volume of 1,844,720 shares suggests consistent investor interest. The stock is likely to trade within a range of $26.50 to $30.50 over the next three months, influenced by clinical trial updates and market conditions.